vVARDIS Holding AG (VVVV) Stock Price & How to Invest

Last updated November 2026

Short answer

VVVV is a regular NYSE listing, so any U.S. brokerage account can hold it. vVARDIS is a Swiss dental company selling Curodont, a drill-free liquid that helps early cavities remineralize. It priced its IPO at $18 on November 12, 2026, below the $21 to $24 range, and closed at ~$14.81 on November 20, 2026, about 18% under the offer price, for roughly $0.78 billion in market value on ~$56 million of trailing revenue, about 14 times sales.

VVVV stock price

As of 2026-11-20, vVARDIS Holding AG (VVVV) last closed at $14.55. Over its trading history so far it has traded between $14.55 and $16.50.

VVVV last close
$14.55
1 day
-3.00%
1 month
n/a
1 year
n/a
Range since listing
$14.55 to $16.50
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or vVARDIS Holding AG's investor relations page. Walnut is informational, not investment advice.

VVVV key stats

At $14.55 on November 20, 2026, vVARDIS Holding AG (VVVV) has a market cap of $771M.

Market cap
$771M

Market cap, P/E and yield are measured at the $14.55 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with vVARDIS Holding AG (VVVV)?

The last two weeks for vVARDIS Holding AG, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • VVVV closed at $14.55 on November 20, 2026, down 11.8% over the past five trading days (from $16.50).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does vVARDIS Holding AG (VVVV) do?

vVARDIS Holding AG is a dental products company based in Zug, Switzerland, run by its co-founders and co-CEOs Haley and Goly Abivardi, two dentists who previously ran a chain of Swiss clinics. Its business is one product family, Curodont, a peptide-containing liquid a dentist applies to an early-stage cavity in a few minutes, without drilling or anaesthetic. The peptides form a scaffold inside the lesion that lets minerals from saliva rebuild the enamel. In the United States the product is sold as Curodont Repair Fluoride Plus, which the FDA regulates as an over-the-counter drug because of its sodium fluoride content. That route got it to market quickly, and it also means the FDA has made no finding on its safety or effectiveness.

The U.S. launch in January 2024 changed the size of the company. Net revenue went from ~$12.2 million in 2024 to ~$30.2 million in 2025 (up 148.5%), then ~$28.6 million in the first half of 2026 alone (up 214%). Preliminary figures in the prospectus put nine-month 2026 revenue at $47.7 million to $49.2 million, against $22.3 million a year earlier. Gross margin reached about 86% after a third-generation manufacturing process came on line. Losses have not closed: the nine-month net loss is estimated at $39.7 million to $41.3 million, interest expense alone ran near $14 million, and the accumulated deficit was ~$256.3 million at June 30, 2026. The company says Curodont has been sold to more than 20,000 of the roughly 110,000 U.S. general dental practices and used on over 3.5 million teeth.

The IPO priced on November 12, 2026 at $18 per Class A share, below the $21 to $24 range, with 9,722,223 shares sold for gross proceeds of about $175 million. Goldman Sachs and J.P. Morgan led the deal, and trading opened on November 13 in a $14 to $18 range. The stock has drifted lower since, within a first-week range of ~$14.00 to ~$16.95, and closed at ~$14.81 on November 20, 2026, about 18% below the IPO price. At that price the company is worth roughly $0.78 billion counting Class A shares plus the founders' Class B voting shares at their one-tenth economic weight, or close to $0.9 billion once the anti-dilution shares owed to its Series B investors are added. That is around 14 times trailing revenue. Apollo invested in April 2026 at a valuation above $1 billion, so public buyers are paying less than that private round. Walnut is not an investment adviser, and this is descriptive context, not a recommendation.

What's driving vVARDIS Holding AG (VVVV)?

1. More U.S. practices, and more use per practice

Curodont reached more than 20,000 of about 110,000 U.S. general dental practices within roughly two and a half years of launch, so most practices have still never ordered it. The company's U.S. team as of September 30, 2026 was 68 key account managers who sign up practices, 9 internal sales representatives focused on reorders, 9 clinical education specialists and a 12-person marketing team. U.S. net revenue rose by about $25 million in the first nine months of 2026, driven by a 112% increase in units of Curodont Repair Fluoride Plus. Growth from here depends on two numbers the company does not fully disclose: how many new practices sign on each quarter, and how often existing ones reorder.

2. AI cavity detection as a referral channel

Early cavities are often missed on X-rays, and a cavity nobody diagnoses is one nobody treats. vVARDIS has partnerships with VideaHealth and Pearl, two AI radiograph-reading companies, and with Henry Schein One to build Curodont into treatment planning in the Dentrix Ascend practice software, so a flagged early lesion can be scheduled for Curodont in the same workflow. The prospectus cites FDA submission data in which AI assistance raised cavity detection from 57.9% to 76.2% for one product, and argues wider AI adoption could enlarge its market by more than 30%. That upside is excluded from the company's own market estimate.

3. Margins and operating leverage

Gross margin rose from ~51.4% in the first half of 2025 to ~86.4% in the first half of 2026, helped by a new manufacturing process and lower logistics costs. The gap is below the gross profit line: selling, general and administrative expense was ~$59.9 million in 2025 and ~$35.1 million in the first half of 2026, more than revenue in both periods. Adjusted EBITDA improved to an estimated loss of about $9.3 million for the first nine months of 2026, from ~$17.1 million a year earlier, which is the trend to track in the first reports as a public company.

4. A stronger balance sheet after the IPO

vVARDIS went into the offering with ~$29.0 million of cash at June 30, 2026 and about $119.8 million of contractual borrowings at the end of 2025, mostly OrbiMed term loans carrying floating rates well into double digits. Net interest cost of $13.8 million to $14.1 million in the first nine months of 2026 was larger than the adjusted EBITDA loss. The roughly $175 million of gross IPO proceeds (net proceeds were estimated near $166 million at the original midpoint) is earmarked for general corporate purposes. How much of it goes to reducing that expensive debt, and how fast, will shape whether reported net losses narrow along with operating losses.

What are the risks to vVARDIS Holding AG (VVVV)?

Almost all revenue comes from one product family, and in the U.S. nearly all of it flows through one distributor: Henry Schein accounted for about 90% of sales in the first half of 2026, up from 62% a year earlier, under an exclusive agreement that runs to December 31, 2029. Heartland Dental, a large dental service organization, is another key customer. Curodont Repair Fluoride Plus is sold under the FDA's over-the-counter route because of its fluoride, and the company itself warns regulators could disagree with that classification and require a different pathway. Dentists already have entrenched, reimbursed options in fluoride varnish, sealants and fillings, and the clinical case for Curodont rests largely on European studies. The company is still losing money, with an accumulated deficit of ~$256.3 million, and carries expensive floating-rate debt. Governance is concentrated: the Abivardi sisters hold all the Class B voting shares and about 87% of voting power, and they have pledged about 10.3 million shares as collateral for CHF 105 million (~$128 million) of personal loans, with talks to pledge up to 2.87 million more. A forced sale of pledged shares would land on the public float. The stock has traded for only a week, priced below its range, has since fallen about 18% under the offer price, and faces a 180-day lock-up expiry in May 2027. It has no analyst coverage yet, and it will report its first full quarter as a public company in 2027.

Is VVVV a buy or a sell?

We give no verdict on vVARDIS Holding AG. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. More U.S. practices, and more use per practice. Curodont reached more than 20,000 of about 110,000 U.S.

The case against. Almost all revenue comes from one product family, and in the U.S.

Read the full bull and bear case on VVVV, including what would have to change to break either one. Walnut is not an investment adviser.

How is vVARDIS Holding AG (VVVV) valued?

Market cap, P/E and dividend yield at today's price are in the VVVV key stats above. The business figures below come from vVARDIS Holding AG's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM through September 2026, preliminary): ~$56M (Q4 2025 plus 9M 2026 midpoint)
  • Revenue (9M 2026, preliminary): ~$47.7M to $49.2M, up ~114% to 121%
  • Gross margin (9M 2026, preliminary): ~86%
  • Net loss (9M 2026, preliminary): ~$39.7M to $41.3M (adjusted EBITDA ~-$9.3M)
  • IPO price and share price: $18.00 IPO; ~$14.81 close on November 20, 2026 (first-week range ~$14.00 to ~$16.95)

As of November 2026: The market value depends on how shares are counted. After the IPO there are about 38.6 million Class A shares plus 143.9 million Class B voting shares held by the founders, but each Class B share carries one-tenth the economic rights of a Class A share, so it counts as about 14.4 million Class A equivalents. Some early press reports quoted a valuation above $4 billion by counting Class B shares as full shares. On ~53.0 million economic shares at ~$14.81 the company is worth ~$0.78 billion, about 14 times trailing revenue of ~$56 million and about 26 times 2025 revenue. No analyst coverage exists yet; the underwriters' quiet period typically ends 25 days after the IPO, which points to early December 2026.

Who competes with vVARDIS Holding AG (VVVV)?

Conventional cavity prevention and repair

Most early cavities today are either watched or drilled and filled. Fluoride varnishes and sealants from Solventum (the former 3M Oral Care), Colgate-Palmolive and others, and composite filling materials from Dentsply Sirona, are the standard of care Curodont has to displace. They are cheap, familiar and widely reimbursed, which is the main barrier vVARDIS names in its prospectus.

Other non-invasive cavity treatments

Silver diamine fluoride, sold in the U.S. as Advantage Arrest by Elevate Oral Care, stops decay cheaply but stains the lesion black and does not rebuild enamel. Resin infiltration such as DMG's Icon seals early lesions between teeth. vVARDIS positions Curodont as the option that is both non-invasive and restorative, and these are the products a dentist compares it with directly.

Listed dental companies investors compare it with

Henry Schein is both vVARDIS's distributor and a listed dental bellwether. Dentsply Sirona, Envista and Switzerland's Straumann are the established dental equipment and consumables names, and Align Technology is the closest example of a single dental product category growing into a large public company. All are profitable or near it and far larger, so they frame valuation more than direct competition.

What stocks are similar to vVARDIS Holding AG (VVVV)?

Other names that sit close to VVVV: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in vVARDIS Holding AG (VVVV)

There are three common ways to get VVVV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VVVV sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VVVV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on vVARDIS Holding AG (VVVV)

vVARDIS is a fast-growing, still unprofitable one-product dental company priced at about 14 times trailing sales, with founder voting control, a 90% distributor concentration and a share price that has slipped further below its IPO in its first week of trading.

More on vVARDIS Holding AG (VVVV)

Whether VVVV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VVVV a buy or a sell?, and where the stock could go from here in the VVVV stock forecast.

For income investors, whether VVVV pays a dividend and how the payout looks is covered in does VVVV pay a dividend? And to weigh VVVV against a peer, read the full side-by-side comparisons: VVVV vs SOLV and VVVV vs CL.

Wondering how VVVV fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about vVARDIS Holding AG

Ask Walnut's AI anything about VVVV and see how it fits what you own.

FAQ

How can you invest in vVARDIS stock?

+

vVARDIS Class A shares trade on the New York Stock Exchange under the ticker VVVV, so they can be held in any brokerage account that offers U.S.-listed stocks, including accounts that allow fractional shares. The stock began trading on November 13, 2026, after the IPO priced at $18 the evening before. It traded between about $14 and $18 on its first day, was near $16.50 that weekend, and closed at ~$14.81 on November 20, 2026. Only the Class A shares are listed. The Class B voting shares are held entirely by the two founders and are not traded. The company is incorporated in Switzerland and reports its results in U.S. dollars. Walnut does not tell anyone whether to own it.

What is Curodont?

+

vVARDIS sells Curodont, a family of dental products built on self-assembling peptides. A dentist applies the liquid to an early-stage cavity, the peptides form a structure inside the porous lesion, and minerals already present in saliva move in to rebuild the enamel. The procedure takes a few minutes and needs no drill or needle. The U.S. product, Curodont Repair Fluoride Plus, generates most of the revenue. Outside the U.S. the company also sells Curodont Protect, a version it protects through trade secrets, without patents. Its material patents on the peptide formulations are expected to expire between 2033 and 2047. Patent filings also cover further uses of the same technology, such as decay around existing fillings and gum disease.

How fast is vVARDIS growing?

+

Net revenue was ~$12.2 million in 2024, the year of the U.S. launch, ~$30.2 million in 2025, and ~$28.6 million in just the first half of 2026, up 214% on the same period a year earlier. Preliminary results in the prospectus put revenue for the first nine months of 2026 at $47.7 million to $49.2 million, up about 114% to 121% from $22.3 million. Growth rates are slowing as the base gets larger. Adding the fourth quarter of 2025 (about $7.9 million) to the nine-month midpoint gives trailing twelve-month revenue of roughly $56 million. Almost all of the increase came from the U.S., where unit sales of Curodont Repair Fluoride Plus rose about 112%.

Is vVARDIS profitable?

+

No. The company lost ~$56.4 million in 2025 and ~$27.8 million in the first half of 2026, and it estimates a net loss of $39.7 million to $41.3 million for the first nine months of 2026, roughly flat with a year earlier. Two things sit behind that. Selling and administrative costs, mostly the U.S. sales force, marketing and education, exceed revenue. Interest on its OrbiMed term loans and other debt also ran at $13.8 million to $14.1 million for the nine months. On the company's adjusted EBITDA measure, which excludes interest, share-based pay and several one-off items, the nine-month loss narrowed to about $9.3 million from ~$17.1 million. Gross margin of about 86% means each additional sale is profitable at the product level; the question is how quickly revenue outgrows fixed costs.

Why did the vVARDIS IPO price below its range?

+

vVARDIS marketed its shares at $21 to $24 and priced at $18 on November 12, 2026, raising about $175 million from 9,722,223 shares. Reuters, as cited by Dealroom, tied the weaker pricing to a tech-led selloff and broader market uncertainty that week. The company sold more shares than the 8.33 million in its final pre-pricing filing to make up part of the gap, which kept proceeds near $175 million. The first-day trading range of $14 to $18 meant the stock never traded above the offer price on day one, and it was near $16.50 afterward, about 8% below the IPO price, then ~$14.81 by November 20, about 18% below it. Underwriters also hold a 30-day option on up to 1,458,333 additional shares. The offering was expected to close on or about November 16, 2026.

What is vVARDIS's market cap?

+

After the offering there are about 38.6 million Class A shares outstanding and 143.9 million Class B voting shares owned by the founders. A Class B share has one-tenth the par value of a Class A share, and dividends and other distributions follow par value, so ten Class B shares carry the same economic claim as one Class A share. Counted that way there are about 53.0 million Class A equivalent shares, worth ~$0.78 billion at ~$14.81 on November 20, 2026 (~$0.87 billion at the ~$16.50 seen just after the IPO). Holders of the company's Series B preferred shares also have anti-dilution rights to receive additional Class A shares at par value, and the lower IPO price increases that number, which pushes the figure toward ~$0.9 billion at the current price. Reports quoting $4 billion or more counted every Class B share as a full share.

Who controls vVARDIS?

+

The co-founders and co-CEOs, sisters Haley and Goly Abivardi, control it. Through their holdings and vVardis Investment Holding AG they own all 143.9 million Class B voting shares. Every share of either class has one vote, but the Class B shares cost one-tenth as much in par value, so the founders hold about 87% of the combined voting power after the IPO while owning a much smaller share of the economics. That lets them decide director elections, changes to the articles and any merger. The Class B shares convert to Class A under certain sunset events, such as a founder leaving the board. Apollo Global Management invested in April 2026 at a valuation above $1 billion, and OrbiMed holds warrants alongside its loans. The founders have also pledged shares against personal loans.

How does Curodont reach U.S. dentists?

+

vVARDIS uses a hybrid model. Henry Schein is the exclusive U.S. distributor (and exclusive in the U.K. until the end of 2026), handling ordering, logistics and its own sales reach, while vVARDIS runs a specialized team that signs up practices, drives reorders and trains clinicians. Henry Schein accounted for about 90% of sales in the first half of 2026, and the agreement runs to December 31, 2029 with automatic one-year renewals. Large dental service organizations such as Heartland Dental are key customers. Curodont is also taught in more than 50 U.S. and European dental programs, which the company estimates reach about 30% of graduating U.S. dentists.

How has VVVV stock performed since its IPO?

+

vVARDIS priced at $18 on November 12, 2026 and has not closed above that level. It traded between about $14 and $18 on November 13, its first day, held near $16.50 into that weekend, and closed at ~$14.81 on November 20, 2026, about 18% below the offer price. Its trading range so far is ~$14.00 to ~$16.95. A one-week record says little about a company's prospects, and no analysts cover the stock yet. Walnut is not an investment adviser.

When will vVARDIS report earnings as a public company?

+

The company has not announced a date. The prospectus already included preliminary nine-month 2026 figures (revenue of $47.7 million to $49.2 million and a net loss of $39.7 million to $41.3 million), so the first scheduled report is likely to be full-year 2026 results in early 2027. Analyst coverage from the underwriting banks typically begins once the quiet period ends, about 25 days after the November 13 listing.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with vVARDIS Holding AG's investor relations page or your broker before making investment decisions.